| 西罗莫司治疗静脉畸形研究现状 |
| |
| 引用本文： | 郑家伟. 西罗莫司治疗静脉畸形研究现状[J]. 中国口腔颌面外科杂志, 2020, 18(6): 553-558. DOI: 10.19438/j.cjoms.2020.06.001 |
| |
| 作者姓名： | 郑家伟 |
| |
| 作者单位： | 上海交通大学医学院附属第九人民医院·口腔医学院 口腔颌面-头颈肿瘤科,国家口腔疾病临床医学研究中心,上海市口腔医学重点实验室,上海市口腔医学研究所,上海 200011 |
| |
| 基金项目： | 国家自然科学基金(81771087,82071130) |
| |
| 摘 要： | 静脉畸形是临床上最常见的血管畸形,大多数是由于编码TIE2或PI3K基因中的功能获得性体细胞突变引起的。复杂或顽固性静脉畸形的治疗,仍然是临床上面临的难题和挑战。西罗莫司为mTOR抑制剂,是第一个用于静脉畸形的靶向药物,其疗效和安全性近年来颇受关注。本文就西罗莫司用于治疗静脉畸形的相关问题进行综述。
|
| 关 键 词： | 静脉畸形 西罗莫司 雷帕霉素 mTOR抑制剂 靶向分子治疗 |
| 收稿时间： | 2020-10-20 |
| 修稿时间： | 2020-10-30 |
Advances of using sirolimus to treat venous malformations |
| |
| ZHENG Jia-wei. Advances of using sirolimus to treat venous malformations[J]. China Journal of Oral and Maxillofacial Surgery, 2020, 18(6): 553-558. DOI: 10.19438/j.cjoms.2020.06.001 |
| |
| Authors: | ZHENG Jia-wei |
| |
| Affiliation: | Department of Oromaxillofacial Head and Neck Oncology,Shanghai Ninth People's Hospital,College of Stomatology,Shanghai Jiao Tong University School of Medicine; National Clinical Research Center for Oral Diseases; Shanghai Key Laboratory of Stomatology & Shanghai Research Institute of Stomatology. Shanghai 200011, China |
| |
| Abstract: | Venous malformations are the most common vascular malformations seen in the clinic, most of them are caused by gain-of-function somatic mutations in the genes encoding TIE2 or PI3K. Management of complicated or refractory lesions is still a great challenge for clinicians. mTOR inhibitor sirolimus is the first targeting agent for venous malformation treatment, its efficacy and safety have attracted much attention in recent years. This article reviewed the related problems and advances of using sirolimus to treat venous malformationsl. |
| |
| Keywords: | Venous malformations Sirolimus Rapamycin mTOR inhibitor Targeted molecular therapy |
|
| 点击此处可从《中国口腔颌面外科杂志》浏览原始摘要信息 |
|
点击此处可从《中国口腔颌面外科杂志》下载全文 |
